161 related articles for article (PubMed ID: 32484625)
1. The Influence of Supportive Oncodermatology Interventions on Patient Quality of Life: A Cross-Sectional Survey.
Aizman L; Nelson K; Sparks AD; Friedman AJ
J Drugs Dermatol; 2020 May; 19(5):477-482. PubMed ID: 32484625
[TBL] [Abstract][Full Text] [Related]
2. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
[TBL] [Abstract][Full Text] [Related]
3. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study.
Barrios DM; Phillips GS; Freites-Martinez A; Hsu M; Ciccolini K; Skripnik Lucas A; Marchetti MA; Rossi AM; Lee EH; Deng L; Markova A; Myskowski PL; Lacouture ME
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1340-1347. PubMed ID: 31856311
[TBL] [Abstract][Full Text] [Related]
4. The Role of Oncodermatology in the Care of Patients Receiving Cancer Therapy.
Skripnik Lucas A; Ciccolini K
Semin Oncol Nurs; 2017 Nov; 33(4):393-401. PubMed ID: 28943034
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of patient-reported outcome instruments of nonmelanoma skin cancer in the dermatologic population.
Lee EH; Klassen AF; Nehal KS; Cano SJ; Waters J; Pusic AL
J Am Acad Dermatol; 2013 Aug; 69(2):e59-67. PubMed ID: 23102770
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study.
Dalenc F; Ribet V; Rossi AB; Guyonnaud J; Bernard-Marty C; de Lafontan B; Salas S; Ranc Royo AL; Sarda C; Levasseur N; Massabeau C; Levecq JM; Dulguerova P; Guerrero D; Sibaud V
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 28833787
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients.
Phillips GS; Freites-Martinez A; Hsu M; Skripnik Lucas A; Barrios DM; Ciccolini K; Marchetti MA; Deng L; Myskowski PL; Lee EH; Markova A; Lacouture ME
J Am Acad Dermatol; 2018 Jun; 78(6):1102-1109. PubMed ID: 29273489
[TBL] [Abstract][Full Text] [Related]
8. Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study.
Barbu MA; Niţipir C; Voiosu T; Giurcăneanu C
Rom J Intern Med; 2018 Jun; 56(2):96-101. PubMed ID: 29360630
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Frequency of "Not Relevant" Responses on the Dermatology Life Quality Index by Sociodemographic Characteristics of Patients With Psoriasis.
Barbieri JS; Shin DB; Syed MN; Takeshita J; Gelfand JM
JAMA Dermatol; 2020 Apr; 156(4):446-450. PubMed ID: 32101261
[TBL] [Abstract][Full Text] [Related]
10. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M; Sibaud V
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
[TBL] [Abstract][Full Text] [Related]
11. Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients' Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers.
Kafatos G; Dube S; Burdon P; Demonty G; Flinois A; Leclerc M; Lowe K; Feudjo-Tepie M; Segaert S
Clin Colorectal Cancer; 2020 Jun; 19(2):100-108.e9. PubMed ID: 32113902
[TBL] [Abstract][Full Text] [Related]
12. Concerns and Treatment Satisfaction in Patients Being Treated With Azelaic Acid Foam for Rosacea.
Williamson T; Cameron J; McLeod K; Turner B; Quillen A; LaRose A; Lott J; Gaiser A
J Drugs Dermatol; 2019 Apr; 18(4):381-386. PubMed ID: 31013011
[TBL] [Abstract][Full Text] [Related]
13. Severity and management of psoriasis within primary care.
Wade AG; Crawford GM; Young D; Leman J; Pumford N
BMC Fam Pract; 2016 Oct; 17(1):145. PubMed ID: 27737638
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Dermatology Life Quality Index and the Children's Dermatology Life Quality Index in assessment of quality of life in patients with psoriasis aged 16-17 years.
van Geel MJ; Maatkamp M; Oostveen AM; de Jong EM; Finlay AY; van de Kerkhof PC; Seyger MM
Br J Dermatol; 2016 Jan; 174(1):152-7. PubMed ID: 26361284
[TBL] [Abstract][Full Text] [Related]
15. Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea.
Byun DW; Moon SH; Kim T; Lee HH; Park HM; Kang MI; Ha YC; Chung HY; Yoon BK; Kim TY; Chae SU; Shin CS; Yang KH; Lee JH; Chang JS; Kim SH; Kim IJ; Koh JM; Jung JH; Yi KW; Yoo JJ; Chung DJ; Lee YK; Yoon HK; Hong S; Kim DY; Baek KH; Kim HJ; Kim YJ; Kang S; Min YK
J Bone Miner Metab; 2019 May; 37(3):563-572. PubMed ID: 30238428
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies.
Chan A; Cameron MC; Garden B; Boers-Doets CB; Schindler K; Epstein JB; Choi J; Beamer L; Roeland E; Russi EG; Bensadoun RJ; Teo YL; Chan RJ; Shih V; Bryce J; Raber-Durlacher J; Gerber PA; Freytes CO; Rapoport B; LeBoeuf N; Sibaud V; Lacouture ME
Support Care Cancer; 2015 Aug; 23(8):2231-44. PubMed ID: 25564221
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study.
Lee J; Lim J; Park JS; Kim M; Kim TY; Kim TM; Lee KH; Keam B; Han SW; Mun JH; Cho KH; Jo SJ
Cancer Res Treat; 2018 Oct; 50(4):1186-1193. PubMed ID: 29237254
[TBL] [Abstract][Full Text] [Related]
18. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
Joshi SS; Ortiz S; Witherspoon JN; Rademaker A; West DP; Anderson R; Rosenbaum SE; Lacouture ME
Cancer; 2010 Aug; 116(16):3916-23. PubMed ID: 20564072
[TBL] [Abstract][Full Text] [Related]
19. The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients.
Ra HS; Shin SJ; Kim JH; Lim H; Cho BC; Roh MR
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e53-9. PubMed ID: 22329482
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy in oncology patients and skin: Pharmaceutical and dermocosmetic management.
Varvaresou A; Iakovou K; Mellou F; Myrogiannis D; Papageorgiou S
J Cosmet Dermatol; 2020 Apr; 19(4):782-788. PubMed ID: 31769600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
